Accepted at 12:37 a.m. Oct, 07, 2025 by Jwill
Author: Jwill
Co-authors: andrewmathias8
Related Note: 1485042620859
Rationale for change

NBME CCSSA 10
67 yo pt: has radiating pain and asks most appropriate pharmacotherapy
answer: add oral nortriptyline at bedtime

We do have nid:1485042614659 that points out that secondary amines "have the least anticholinergic effects"

But I think this addition to this card helps to emphasize that these may still be seen in the elderly population

AMBOSS supports
Source: AMBOSS - https://next.amboss.com/us/article/_N05dg?q=Tricyclic%20antidepressants#IncYu10

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#UWorld::Step::6682 #AK_Step2_v12::#B&B::13_Psych::04_Psychopharmacology::01_Antidepressants #AK_Step2_v12::Original_decks::Dorian::neuro::uw #AK_Step2_v12::Original_decks::Dorian::psych::fapsych::pharm #AK_Step2_v12::#Resources_by_rotation::Psych::fapsych::pharm #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry #AK_Step2_v12::Original_decks::Dorian::im::uw::endocrine #AK_Step1_v12::#AMBOSS::VPaGdk #AK_Step2_v12::#Resources_by_rotation::Psych::nbme #AK_Step2_v12::Original_decks::Dorian::fam::ome::psych::pharm #AK_Step2_v12::!Shelf::FM::no_dupes #AK_Step2_v12::#UWorld::COMLEX::103172 #AK_Step2_v12::Original_decks::Dorian::im::uw::neuro #AK_Step2_v12::#Resources_by_rotation::IM::uw::endocrine_diabetes_metabolism::endocrine_diabetes_metabolism_dorian #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#UWorld::COMLEX::23688 #AK_Step2_v12::#Subjects::Psychiatry::05_Mood_Disorders::Major_Depressive_Disorder::Management::TCAs #AK_Step1_v12::#FirstAid::13_Psych::02_Pathology::40_Psychiatric_emergencies::*Tricyclic_Antidepressant_Overdose::Pathophysiology #AK_Step2_v12::Original_decks::Dorian::psych::nbme #AK_Step2_v12::#UWorld::Step::16032 #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Step2_v12::#Resources_by_rotation::Neuro::uw::dorian #AK_Step2_v12::#AMBOSS::#Self-Assessment::2024::Block-2 #PANCE::BEHAVIORAL::depression #AK_Step2_v12::#Resources_by_rotation::FM::ome::psych::pharm #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::09_Tricyclic_antidepressants #AK_Step2_v12::!Shelf::Psych::no_dupes #AK_Step2_v12::#Subjects::Psychiatry::05_Mood_Disorders::Major_Depressive_Disorder::Management::TCAs::Side_Effects #AK_Step1_v12::#Bootcamp::Psychiatry::09_Pharmacology::03_Tricyclic_Antidepressants #AK_Step1_v12::#AMBOSS::Jiass4 #AK_Step3_v12::#UWorld::12726 #AK_Step1_v12::#B&B::16_Neuro::04_Autonomic_Nervous_System::06_Cholinergic_Drugs::Extra #AK_Step1_v12::#Pixorize::03_Pharmacology::17_Psych_Pharm::06_Tricyclic_Antidepressants_(TCAs) #AK_Step1_v12::#B&B::19_Psych::04_Pharm::01_Antidepressants::Extra #AK_Step1_v12::#Bootcamp::Pharmacology::04_Side_Effects_and_Toxins::01_Age_Considerations_for_Pharmacokinetics #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::21_Tricyclic_Antidepressants #AK_Step2_v12::#AMBOSS::Jiass4 #PANCE::EOR::PSYCH #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::02_Antidepressants_&_Anxiolytics::02_Tricyclic_Antidepressants #AK_Step2_v12::#NBME #AK_Step1_v12::#B&B::16_Neuro::05_Other_Neurology_Topics::07_Delirium::Extra #AK_Step2_v12::!Shelf::Neuro #AK_Step1_v12::#UWorld::Step::575 #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::!Shelf::IM